ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$105.04
−1.82%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 5035.34x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 17.55x
- Price / sales
- —
- Price / cash flow
- -76.32x
Enterprise value
- Enterprise value
- $8.6B
- EV / sales
- —
- EV / EBITDA
- -24.94x
- EV / EBIT
- -30.48x
- Market cap
- $9.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Dec 1, 2025